FCP OP MEDICAL BioHealth Trends FCP OP ... - Sal. Oppenheim

More documents

Recommendations

Info

HEALTHCARE MARKET Pipeline: development of medical drugs in the USA DISEASE PRODUCTS IN THE PIPELINE CCancer 861 Infections 338 Autoimmune diseases 59 HIV/AIDS 97 Heart 312 Diabetes 183 Total 1850 Source: Pharmaceutical Research and Manufacturers of America (PhRMA) As of: 2010 06/30/2012| Page 10 <strong>Oppenheim</strong> Asset Management Services S.à r.l.
HEALTHCARE MARKET Pharma-equities: Since 2000 end of growth era 450 400 350 300 250 200 AMEX-PHARMA-INDEX (USD) EARNINGS GROWTH AND PER Period: 11/1996 to 06/2012 150 11/96 11/98 11/00 11/02 11/04 11/06 11/08 11/10 11/12 Source: Datastream PER 2012 expected PER 2013 expected Expected sales growth 2011-2014 2011 2014 Expected earnings growth g 2011-2014 US Big- Pharma EU Big-Pharma 11,9 12,0 11 11,7 7 10 10,7 7 0,6% 3,9% 2,3% 8,0% Source: Medical Strategy GmbH, Gräfelfing bei München, yahoo! Finance (5.8.2011), Citi (29.12.2011) 06/30/2012| Page 11 <strong>Oppenheim</strong> Asset Management Services S.à r.l.
Page 1 and 2: OPPENHEIM ASSET MANAGEMENT SERVICES
Page 3 and 4: FUND ORIENTATION Small and mid-cap
Page 5 and 6: FUND ORIENTATION The investment spe
Page 7 and 8: HEALTHCARE MARKET Why invest in the
Page 9: HEALTHCARE MARKET Growth through in
Page 13 and 14: HEALTHCARE MARKET Big-Biotech-Equit
Page 15 and 16: INVESTMENT PROCESS Basis for a succ
Page 17 and 18: INVESTMENT PROCESS Example case: Im
Page 19 and 20: GROWTH IN DIFFERENT MARKET PHASES C
Page 21 and 22: GROWTH IN DIFFERENT MARKET PHASES C
Page 23 and 24: STOCKPICKING AND PORTFOLIO STRUCTUR
Page 31 and 32: PERFORMANCE Multiple awards SAUREN
Page 33 and 34: PERFORMANCE Performance: FCP OP MED
Page 35 and 36: PERFORMANCE Share class EUR H far-r
Page 37 and 38: PERFORMANCE FCP OP MEDICAL BioHealt
Page 39 and 40: SUMMARY Current arguments in favour
Page 41 and 42: OUTLOOK FCP OP MEDICAL BioHealth-Tr
Page 43 and 44: OUTLOOK Basis for outperformance of
Page 45 and 46: ANNEX: FUND DATA AND NOTE ABOUT RIS
Page 47: Disclaimer Management company: Oppe

FCP OP MEDICAL BioHealth Trends FCP OP ... - Sal. Oppenheim

Create successful ePaper yourself

Delete template?

Save as template?